靶向调控HIF-1α-VEGF-VEGFR-2通路治疗恶性肿瘤的新进展

doi:10.3760/cma.j.issn.1673-422X.2017.06.014

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (6): 456-.doi: 10.3760/cma.j.issn.1673-422X.2017.06.014

靶向调控HIF-1α-VEGF-VEGFR-2通路治疗恶性肿瘤的新进展

孙菲，汪建林，于静萍

213003常州，南京医科大学附属常州第二人民医院放疗科

出版日期:2017-06-08 发布日期:2017-06-16
通讯作者: 于静萍 E-mail:yujingping700420@sina.com
基金资助:
常州市科技支撑社会发展项目(CE20125021、CE20165024)；常州市高层次卫生人才培养计划（2016C2BJ007）;常州市科技局应用基础研究项目（CJ20159050）；江苏省卫生厅指导性科研项目(Z201220)；常州市卫生局重大项目(ZD201105)

Research advances of cancer therapy targeting HIF-1α-VEGF-VEGFR-2 signaling pathway for malignant tumors

Sun Fei, Wang Jianlin, Yu Jingping

Department of Radiation Oncology, Second Changzhou People′s Hospital Affiliated to Nanjing Medical University, Changzhou 213003, China

Online:2017-06-08 Published:2017-06-16
Contact: Yu Jingping E-mail:yujingping700420@sina.com
Supported by:
Changzhou Scientific and Technological Support Social Development Project (CE20125021, CE20165024); Changzhou HighLevel Heath Personnel Trainning Program (2016C2BJ007); Changzhou Municipal Science and Technology Bureau Basic Research Project (CJ20159050); Jiangsu Province Health Department Guided Research Project (Z201220); Changzhou Health Bureau Major Project (ZD201105)

摘要/Abstract

摘要： 乏氧诱导因子1α（HIF1α）血管内皮生长因子（VEGF）血管内皮生长因子受体2（VEGFR2）通路在调控肿瘤新生血管的形成中发挥着重要的作用，此通路的激活与恶性肿瘤的侵袭和转移密切相关。

关键词: 肿瘤, 新生血管化, 病理性, 血管内皮生长因子类, 受体, 血管内皮生长因子, 信号传导

Abstract: Hypoxia inducible factor1α (HIF1α)vascular endothelial growth factor (VEGF)vascular endothelial growth factor receptor2 (VEGFR2) signaling pathway plays a vital role in the regulation of neovascularization, and the activation of this pathway is closely related with tumor invasion and metastasis.

Key words: Neoplasms, Neovascularization, pathologic, Vascular endothelial growth factors, Receptors, vascular endothelial growth factor, Signal transduction

孙菲，汪建林，于静萍. 靶向调控HIF-1α-VEGF-VEGFR-2通路治疗恶性肿瘤的新进展[J]. 国际肿瘤学杂志, 2017, 44(6): 456-.

Sun Fei, Wang Jianlin, Yu Jingping. Research advances of cancer therapy targeting HIF-1α-VEGF-VEGFR-2 signaling pathway for malignant tumors[J]. Journal of International Oncology, 2017, 44(6): 456-.

参考文献

［1］ Jung HJ, Kim Y, Ju YS, et al. Antiangiogenic activity of herboxidiene via downregulation of vascular endothelial growth factor receptor2 and hypoxiainducible factor1α［J］. Arch Pharm Res, 2015, 38(9): 1728-1735. DOI: 10.1007/s1227201506254. ［2］ Park MH, Choi KY, Jung Y, et al. Phospholipase D1 protein coordinates dynamic assembly of HIF1αPHDVHL to regulate HIF1α stability［J］. Oncotarget, 2014, 5(23): 11857-11872. ［3］ Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells 1［J］. Bioch Pharmacol, 2001, 61(8): 947-954. ［4］ Zhu H, Feng Y, Zhang J, et al. Inhibition of hypoxia inducible factor 1α expression suppresses the progression of esophageal squamous cell carcinoma［J］. Cancer Biol Ther, 2011, 11(11): 981-987. ［5］ Zhao T, Zhu Y, Morinibu A, et al. HIF1mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs［J］. Sci Rep, 2014, 4: 3793. DOI: 10.1038/srep03793. ［6］ Ikezawa Y, SakakibaraKonishi J, Mizugaki H, et al. Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer［J］. Int J Clin Oncol, 2017, 22(1): 59-69. DOI: 10.1007/s1014701610318. ［7］ Srinivasan B, Johnson TE, Xing C. Chalconebased inhibitors against hypoxiainducible factor 1—structure activity relationship studies［J］. Bioorg Med Chem Lett, 2011, 21(1): 555-557. DOI: 10.1016/j.bmcl.2010.10.063. ［8］ Wang L, Chen G, Lu X, et al. Novel chalcone derivatives as hypoxiainducible factor (HIF)1 inhibitor: synthesis, antiinvasive and antiangiogenic properties［J］. Eur J Med Chem, 2015, 89: 88-97. DOI: 10.1016/j.ejmech.2014.10.036. ［9］ Wang LH, Jiang XR, Yang JY, et al. SYP5, a novel HIF1 inhibitor, suppresses tumor cells invasion and angiogenesis［J］. Eur J Pharmacol, 2016, 791: 560-568. DOI: 10.1016/j.ejphar.2016.09.027. ［10］ Grothey A. VEGF inhibition beyond tumour progression［J］. Lancet Oncol, 2013, 14(1): 2-3. DOI: 10.1016/S14702045(12)705168. ［11］吴军, 王婧, 曹邦伟. 抗肿瘤血管生成药物不良反应的发生机制及处理［J］. 医学综述, 2016, 22(16): 3154-3157. DOI: 10.3969/j.issn.10062084.2016.16.010. ［12］ Martín M, Loibl S, Von MG, et al. Phase Ⅲ trial evaluating the addition of bevacizumab to endocrine therapy as firstline treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study［J］. J Clin Oncol, 2015, 33(9): 1045-1052. DOI: 10.1200/JCO.2014.57.2388. ［13］ Flaherty KT, Manola JB, Pins M, et al. Best: a randomized phase Ⅱ study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with Bevacizumab, Sorafenib, and Temsirolimus in advanced renal cell carcinoma—a trial of the ECOGACRIN Cancer Research Group (E2804)［J］. J Clin Oncol, 2015, 33(21): 2384-2391. DOI: 10.1200/JCO.2015.60.9727. ［14］ Chong DQ, Manalo M, Imperial M, et al. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer［J］. Asia Pac J Clin Oncol, 2016, 12(3): 275-283. DOI: 10.1111/ajco.12496. ［15］ Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase Ⅲ randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen［J］. J Clin Oncol, 2012, 30(28): 3499-3506. ［16］ Allen JW, Moon J, Redman M, et al. Southwest Oncology Group S0802: a randomized, phase Ⅱ trial of weekly topotecan with and without zivaflibercept in patients with platinumtreated smallcell lung cancer［J］. J Clin Oncol, 2014, 32(23): 2463-2470. DOI: 10.1200/JCO.2013.51.4109. ［17］ Liu F, Liu Q, Wang G, et al. Ramucirumab in metastatic renal cell carcinoma: the sex, race, and age issues［J］. Cancer, 2014, 120(15): 2379. DOI: 10.1002/cncr.28741. ［18］ Mackey JR, RamosVazquez M, Lipatov O, et al. Primary results of ROSE/TRIO12, a randomized placebocontrolled phase Ⅲ trial evaluating the addition of ramucirumab to firstline docetaxel chemotherapy in metastatic breast cancer［J］. J Clin Oncol, 2015, 33(2): 141-148. DOI: 10.1200/JCO.2014.57.1513. ［19］ Garcia JA, Hudes GR, Choueiri TK, et al. A phase 2, singlearm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy［J］. Cancer, 2014, 120(11): 1647-1655. DOI: 10.1002/cncr.28634. ［20］ Vennepureddy A, Singh P, Rastogi R, et al. Evolution of ramucirumab in the treatment of cancera review of literature［J］. J Oncol Pharm Pract, 2016, In press. ［21］ Marotta V, Sciammarella C, Capasso M, et al. Preliminary data of VEGFA and VEGFR2 polymorphisms as predictive factors of radiological response and clinical outcome in iodinerefractory differentiated thyroid cancer treated with sorafenib［J］. Endocrine, 2016, In press. DOI: 10.1007/s1202001612006. ［22］ Ibrahim N, Yu Y, Walsh WR, et al. Molecular targeted therapies for cancer: sorafenib monotherapy and its combination with other therapies (review)［J］. Oncol Rep, 2012, 27(5): 1303-1311. DOI: 10.3892/or.2012.1675. ［23］ Ferrari SM, Fallahi P, Politti U, et al. Molecular targeted therapies of aggressive thyroid cancer［J］. Front Endocrinol (Lausanne), 2015, 6: 176. DOI: 10.3389/fendo.2015.00176. ［24］ Qu Z, Wu J, Wu J, et al. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro［J］. J Exp Clin Cancer Res, 2016, 35(1): 159. ［25］ Oh WK, McDermott D, Porta C, et al. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review［J］. Int J Oncol, 2014, 44(1): 5-16. DOI: 10.3892/ijo.2013.2181. ［26］ Ibrahim EM, Kazkaz GA, Abouelkhair KM, et al. Sunitinib adverse events in metastatic renal cell carcinoma: a metaanalysis［J］. Int J Clin Oncol, 2013, 18(6): 1060-1069. DOI: 10.1007/s1014701204972. ［27］ Pokuri VK, Tomaszewski GM, AitOudhia S, et al. Efficacy, safety, and potential biomarkers of sunitinib and transarterial chemoembolization (TACE) combination in advanced hepatocellular carcinoma (HCC): phase Ⅱ trial［J］. Am J Clin Oncol, 2016, In press. ［28］ Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase Ⅲ trial［J］. J Clin Oncol, 2013, 31(32): 4067-4075. DOI: 10.1007/s1014701204972. ［29］ Li J, Qin S, Xu J, et al. Randomized, doubleBlind, placebocontrolled phase Ⅲ trial of apatinib in patients with chemotherapyrefractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］. J Clin Oncol, 2016, 34(13): 1448-1454. DOI: 10.1200/JCO.2015.63.5995. ［30］ Lee HJ, Ji YM, Baek SW. Is treatmentemergent toxicity a biomarker of efficacy of apatinib in gastric cancer?［J］. J Clin Oncol, 2016, 34(31): 3823. DOI: 10.1200/JCO.2016.68.8663. ［31］ Carr BI, Cavallini A, Lippolis C, et al. FluoroSorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery［J］. J Cell Physiol, 2013, 228(2): 292-297. DOI: 10.1002/jcp.24148. ［32］ Kim J, Ulu A, Wan D, et al. Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy［J］. Mol Cancer Ther, 2016, 15(5): 890-898. DOI: 10.1158/15357163.MCT150847. ［33］ Pavlakis N, Sjoquist KM, Martin AJ, et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebocontrolled phase Ⅱ trial［J］. J Clin Oncol, 2016, 4(23): 2728-2735. DOI: 10.1200/JCO.2015.65.1901.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

靶向调控HIF-1α-VEGF-VEGFR-2通路治疗恶性肿瘤的新进展

Research advances of cancer therapy targeting HIF-1α-VEGF-VEGFR-2 signaling pathway for malignant tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价